FDA approves Empaveli for rare kidney diseases
The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals’ Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).